Home/Investors/EcoR1 Capital

EcoR1 Capital

Biotech Investor · 2 portfolio companies

Portfolio

2

Combined Value

$6.6B

Focus Areas

6

Top Stage

Phase 3

Investment Focus

Neuromuscular Disorders Oncology Fibrosis Genetic Diseases Autoimmune Diseases Rare Diseases

Portfolio Companies

Company	Stage	Valuation	Focus
Scholar Rock Holding	Phase 3	$5.1B	Neuromuscular Disorders, Oncology
Intellia Therapeutics	Phase 3	$1.5B	Genetic Diseases, Oncology

Frequent Co-Investors

Other institutional and public shareholders2 shared BlackRock1 shared Vanguard1 shared Atlas Venture1 shared Arch Venture Partners1 shared Fidelity1 shared Fidelity Management & Research Company1 shared Regeneron Pharmaceuticals1 shared